Constipation Management

Introduction to Constipation Management

Constipation can be managed with various treatments, including senna, which is recommended by the American Gastroenterological Association as a potential first-line agent for chronic idiopathic constipation 1

The recommended starting dosage of senna is 8.6-17.2 mg daily, with a maximum of 4 tablets twice per day, and treatment duration should be guided by symptom response rather than a fixed timeframe, as recommended by the American Gastroenterological Association 1
The initial dose of senna is 2-3 teaspoons (10-15 mL) or 8.6-17.2 mg tablets once daily, preferably at bedtime, with dosing titrated based on symptom response and side effects 1
Commercially available tablets typically contain 8-9 mg of sennosides per tablet 1

Senna significantly improves quality of life scores compared to placebo, according to the American Gastroenterological Association, and is an attractive option due to its efficacy, impact on quality of life, over-the-counter availability, and low cost 1
Senna may be used as a first-line agent for chronic idiopathic constipation, with ongoing monitoring for efficacy and side effects 1

Common side effects of senna include abdominal pain/cramping, diarrhea, and nausea, with 83% of participants in clinical trials reducing their daily dose due to side effects 1
Senna is not generally recommended during pregnancy due to potential weak genotoxic effects observed in animal studies 1
Patients should be monitored for side effects, particularly abdominal pain and cramping, which are common at higher doses 1

Senna is suggested as an effective first-line therapy for postoperative constipation, particularly in patients receiving opioids for postoperative pain, as recommended by The Journal of Clinical Oncology and the American Gastroenterological Association 2, 1
A multifaceted approach to minimize postoperative ileus is recommended, including early mobilization, optimized fluid management, and opioid-sparing analgesia, with early oral intake encouraged when appropriate 3
For refractory constipation, consider peripherally acting mu-opioid receptor antagonists (PAMORAs) like methylnaltrexone for opioid-induced constipation, with evidence supporting this approach 2, 4
The use of antibiotics may potentially decrease the efficacy of senna-based products by affecting the colonic bacteria that produce the active metabolites, as reported by the American Gastroenterological Association 1

Sennosides stimulate prostaglandin E2 production and chloride ion secretion, leading to increased colonic peristalsis, changes in luminal water content, and stimulation of bowel movements, as noted by the American Gastroenterological Association 1
Over 90% of sennosides and their metabolites are excreted in feces 1